Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ReNeuron Raises $50M For Stem Cell Trials In Stroke, Limb Ischemia And Sight Loss

This article was originally published in The Pink Sheet Daily

Executive Summary

New and existing investors back early clinical studies by leading U.K. stem cell company ReNeuron, including potential therapies for stroke, limb ischemia, and retinitis pigmentosa, as well as other sight destroying conditions like age-related macular degeneration.

You may also be interested in...



New $80 Million U.K. Asset-Centric Cancer Research Fund Set Up With EU, Charity Funding

The U.K.'s Cancer Research Technology and the European Investment Fund join forces to launch an asset-centric investment fund to bridge the development gap, the third new U.K. fund in two weeks.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840

Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.

Topics

Related Companies

UsernamePublicRestriction

Register

PS076002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel